JP2016530267A5 - - Google Patents

Info

Publication number

JP2016530267A5

JP2016530267A5 JP2016535268A JP2016535268A JP2016530267A5 JP 2016530267 A5 JP2016530267 A5 JP 2016530267A5 JP 2016535268 A JP2016535268 A JP 2016535268A JP 2016535268 A JP2016535268 A JP 2016535268A JP 2016530267 A5 JP2016530267 A5 JP 2016530267A5

Authority

JP

Japan

Prior art keywords

use according

inhibitor

cells

mammal

pharmaceutical composition

Prior art date

2013-10-03

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims 16
• 102100035268 T-cell surface protein tactile Human genes 0.000 claims 16
• 241000124008 Mammalia Species 0.000 claims 11
• 239000003112 inhibitor Substances 0.000 claims 10
• 239000008194 pharmaceutical composition Substances 0.000 claims 8
• 210000004027 cell Anatomy 0.000 claims 6
• 238000000034 method Methods 0.000 claims 5
• 210000001744 T-lymphocyte Anatomy 0.000 claims 4
• 108090000695 Cytokines Proteins 0.000 claims 3
• 102000004127 Cytokines Human genes 0.000 claims 3
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
• 108010074328 Interferon-gamma Proteins 0.000 claims 3
• 230000000694 effects Effects 0.000 claims 3
• 102000019034 Chemokines Human genes 0.000 claims 2
• 108010012236 Chemokines Proteins 0.000 claims 2
• 102100037850 Interferon gamma Human genes 0.000 claims 2
• 206010028980 Neoplasm Diseases 0.000 claims 2
• 239000002246 antineoplastic agent Substances 0.000 claims 2
• 201000011510 cancer Diseases 0.000 claims 2
• 239000003814 drug Substances 0.000 claims 2
• 238000010353 genetic engineering Methods 0.000 claims 2
• 230000008629 immune suppression Effects 0.000 claims 2
• 230000037451 immune surveillance Effects 0.000 claims 2
• 238000004519 manufacturing process Methods 0.000 claims 2
• 238000012216 screening Methods 0.000 claims 2
• 229940124597 therapeutic agent Drugs 0.000 claims 2
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
• 108700012434 CCL3 Proteins 0.000 claims 1
• 102000000013 Chemokine CCL3 Human genes 0.000 claims 1
• 102000001326 Chemokine CCL4 Human genes 0.000 claims 1
• 108010055165 Chemokine CCL4 Proteins 0.000 claims 1
• 108010055166 Chemokine CCL5 Proteins 0.000 claims 1
• 102000001327 Chemokine CCL5 Human genes 0.000 claims 1
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
• 206010062016 Immunosuppression Diseases 0.000 claims 1
• 102000008070 Interferon-gamma Human genes 0.000 claims 1
• 206010027476 Metastases Diseases 0.000 claims 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
• 208000036142 Viral infection Diseases 0.000 claims 1
• 239000003443 antiviral agent Substances 0.000 claims 1
• 229940127089 cytotoxic agent Drugs 0.000 claims 1
• 238000013461 design Methods 0.000 claims 1
• 230000001506 immunosuppresive effect Effects 0.000 claims 1
• 230000002401 inhibitory effect Effects 0.000 claims 1
• 229960003130 interferon gamma Drugs 0.000 claims 1
• 230000004068 intracellular signaling Effects 0.000 claims 1
• 230000009401 metastasis Effects 0.000 claims 1
• 230000028327 secretion Effects 0.000 claims 1
• 230000009385 viral infection Effects 0.000 claims 1